Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03734-1 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Yueying Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jinling Hospital Management Project, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
Numerous randomized controlled trials (RCTs) have investigated PD-1/PD-L1 inhibitor-based combination therapies. The debate surrounding the potential additive clinical benefits of combination of two immune-oncology (IO) therapies for cancer patients persists.
Methods
Both published and grey sources of randomized clinical trials that compared anti-PD-1/PD-L1-based immunotherapy combinations with monotherapy in patients with advanced or metastatic solid tumors were encompassed. The primary outcome was progression-free survival (PFS), and secondary outcomes included objective response rate (ORR), overall survival (OS) and treatment-related adverse events (TRAEs).
Results
Our analysis encompassed 32 studies comprising 10,341 patients, which covered 12 distinct immune-oncology combination regimens. Across all patients, the immunotherapy combinations exhibited the capability to enhance the ORR (OR = 1.23 [95% CI 1.13–1.34]) and extend PFS (HR = 0.91 [95% CI 0.87–0.95]). However, the observed enhancement in OS (HR = 0.96 [95% CI 0.91–1.01]) was of no significance. Greater benefits in terms of PFS (HR = 0.82 [95% CI 0.72 to 0.93]) and OS (HR = 0.85 [95% CI 0.73 to 0.99]) may be particularly pronounced in cases where PD-L1 expression is negative. Notably, despite a heightened risk of any-grade TRAEs (OR = 1.72 [95% CI 1.40–2.11]) and grade greater than or equal to 3 TRAEs (OR = 2.01 [95% CI 1.67–2.43]), toxicity was generally manageable.
Conclusions
This study suggests that incorporating an additional immunotherapy agent with PD-1/PD-L1 inhibitors can elevate the response rate and reduce the risk of disease progression, all while maintaining manageable toxicity. However, there remains a challenge in translating these primary clinical benefits into extended overall survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. bairoushui@163.com.
Förderung
- Jinling Hospital Management Project
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, Y., Han, H., Cheng, J., Cheng, Q., Zhu, S., Zhan, P., Liu, H., Song, Y., & Lv, T. (2024). Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03734-1
Vancouver
Chen Y, Han H, Cheng J, Cheng Q, Zhu S, Zhan P, et al. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03734-1
BibTeX
@article{Chen2024,
author = {Chen, Yueying and Han, Hedong and Cheng, Jing and Cheng, Qinpei and Zhu, Suhua and Zhan, Ping and Liu, Hongbing and Song, Yong and Lv, Tangfeng},
title = {Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03734-1}
}
EUVIMED